Table 3. Univariate and multivariate analyses of patient characteristics and treatments associated with OS.
| Characteristics/treatments |
Univariate analysis |
Multivariate analysis |
||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| Melphalan dose, mg/m2 | 0.001 | 0.111 | ||
| 100 | 3.6 (1.7–7.2) | 2.8 (0.9–8.5) | ||
| 140 | 1.4 (0.8–2.6) | 1.4 (0.5–3.6) | ||
| 200 | 1.0 | 1.0 | ||
| Age at SCT, years | 1.02 (0.9–1.05) | 0.129 | ||
| Induction of chemotherapy | 0.071 | 0.049 | ||
| Yes | 1.6 (0.9–2.8) | 2.7 (1.0–7.6) | ||
| No | 1.0 | 1.0 | ||
| No. organs involved, n | 0.021 | 0.477 | ||
| 1 | 1.0 | 1.0 | ||
| 2/3/4/5 | 1.8 (1.1–3.0) | 1.3 (0.6–3.0) | ||
| Cardiac stage | 0.001 | 0.022 | ||
| I | 1.0 | 1.0 | ||
| II | 1.5 (0.6–3.6) | 1.1 (0.4–2.8) | ||
| III | 5.0 (2–12.4) | 3.5 (1.2–10.5) | ||
| Baseline 24-h creatinine clearance, ml/min | 0.805 | |||
| ⩾50 | 1.0 | |||
| <50 | 0.9 (0.5–1.8) | |||
| Baseline plasma cell | 0.085 | |||
| >10% | 1.6 (0.9–2.6) | |||
| ⩽10% | 1.0 | |||
| Protocol | 0.591 | |||
| 02–031 | 0.9 (0.5–1.7) | |||
| 07–006 | 0.7 (0.3–1.4) | |||
| Off study | 1.0 | |||
Abbreviations: CI, confidence interval; HR, hazard ratio; OS, overall survival; SCT, stem cell transplantation.